Utility of early high dose statins in acute coronary syndrome

Am J Ther. 2012 Sep;19(5):369-76. doi: 10.1097/MJT.0b013e31823735aa.

Abstract

In accordance with the recommendations of the American College of Cardiology/American Heart Association Joint Task Force, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are prescribed before hospital discharge after an episode of acute coronary syndrome. Yet, optimal timing and dosage have not been agreed upon. Recent evidence suggests a pleiotropic mechanism of action including vasoprotective, anti-inflammatory, and antiarrhythmic properties that imply an immediate role for statin medications. Our review suggests that early (<24 hours) high dose (80 mg of atorvastatin) statins may significantly reduce adverse cardiovascular outcomes and may improve long-term mortality.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / mortality
  • Acute Coronary Syndrome / physiopathology
  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / physiopathology
  • Dose-Response Relationship, Drug
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Time Factors
  • United States

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors